Zobrazeno 1 - 10
of 51
pro vyhledávání: '"Michael D. Farwell"'
Autor:
Elizabeth S. McDonald, Austin R. Pantel, Payal D. Shah, Michael D. Farwell, Amy S. Clark, Robert K. Doot, Daniel A. Pryma, Sean D. Carlin
Publikováno v:
JCI Insight, Vol 6, Iss 8 (2021)
BACKGROUND [18F]FluorThanatrace ([18F]FTT) is a radiolabeled poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi) that enables noninvasive quantification of PARP with potential to serve as a biomarker for patient selection for PARPi thera
Externí odkaz:
https://doaj.org/article/d6ab613d6d334089b95b77f1f24d6e3c
Autor:
Lalitha K Shankar, Heiko Schöder, Elad Sharon, Jedd Wolchok, Michael V Knopp, Richard L Wahl, Benjamin M Ellingson, Nathan C Hall, Martin J Yaffe, Alexander J Towbin, Michael D Farwell, Daniel Pryma, Tina Young Poussaint, Chadwick L Wright, Lawrence Schwartz, Mukesh Harisinghani, Umar Mahmood, Anna M Wu, David Leung, Elisabeth G E de Vries, Ying Tang, Gillian Beach, Steven A Reeves
Publikováno v:
Lancet Oncology. 24(3):e133-e143
As the immuno-oncology field continues the rapid growth witnessed over the past decade, optimising patient outcomes requires an evolution in the current response-assessment guidelines for phase 2 and 3 immunotherapy clinical trials and clinical care.
Autor:
Kimberly J. Edwards, Bryan Chang, Hasan Babazada, Katheryn Lohith, Daniel H. Park, Michael D. Farwell, Mark A. Sellmyer
Publikováno v:
Cancer Immunol Res
Immune checkpoint inhibitors (ICI) have been effective in treating a subset of refractory solid tumors, but only a small percentage of treated patients benefit from these therapies. Thus, there is a clinical need for reliable tools that allow for the
Autor:
Mark A. Sellmyer, Michael D. Farwell, Daniel H. Park, Katheryn Lohith, Hasan Babazada, Bryan Chang, Kimberly J. Edwards
Supplementary Data from Using CD69 PET Imaging to Monitor Immunotherapy-Induced Immune Activation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa8316233ef03976b13613ed11b61a8e
https://doi.org/10.1158/2326-6066.22545642
https://doi.org/10.1158/2326-6066.22545642
Autor:
Mark A. Sellmyer, Michael D. Farwell, Daniel H. Park, Katheryn Lohith, Hasan Babazada, Bryan Chang, Kimberly J. Edwards
Immune checkpoint inhibitors (ICI) have been effective in treating a subset of refractory solid tumors, but only a small percentage of treated patients benefit from these therapies. Thus, there is a clinical need for reliable tools that allow for the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::606b201f6793dfc88f9a3871110842e2
https://doi.org/10.1158/2326-6066.c.6550992
https://doi.org/10.1158/2326-6066.c.6550992
Autor:
Mark A. Sellmyer, Ellen Puré, Steven M. Albelda, Carl H. June, Michael D. Farwell, Kimberly J. Edwards, Kexiang Xu, Katheryn Lohith, Maria Liousia, Decheng Song, John Scholler, Leslie Todd, Zebin Xiao, Estela Noguera-Ortega, Iris K. Lee
Supplementary Data from Monitoring Therapeutic Response to Anti-FAP CAR T Cells Using [18F]AlF-FAPI-74
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::653c5550bfef8e854c6adbed18086a90
https://doi.org/10.1158/1078-0432.22488903
https://doi.org/10.1158/1078-0432.22488903
Autor:
Mark A. Sellmyer, Ellen Puré, Steven M. Albelda, Carl H. June, Michael D. Farwell, Kimberly J. Edwards, Kexiang Xu, Katheryn Lohith, Maria Liousia, Decheng Song, John Scholler, Leslie Todd, Zebin Xiao, Estela Noguera-Ortega, Iris K. Lee
Purpose:Despite the success of chimeric antigen receptor (CAR) T-cell therapy against hematologic malignancies, successful targeting of solid tumors with CAR T cells has been limited by a lack of durable responses and reports of toxicities. Our under
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63908ed243288c17d971b25c5c1ecafe
https://doi.org/10.1158/1078-0432.c.6532830.v1
https://doi.org/10.1158/1078-0432.c.6532830.v1
Autor:
Mark A. Sellmyer, Ellen Puré, Steven M. Albelda, Carl H. June, Michael D. Farwell, Kimberly J. Edwards, Kexiang Xu, Katheryn Lohith, Maria Liousia, Decheng Song, John Scholler, Leslie Todd, Zebin Xiao, Estela Noguera-Ortega, Iris K. Lee
Supplementary Figure from Monitoring Therapeutic Response to Anti-FAP CAR T Cells Using [18F]AlF-FAPI-74
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43717d861d181e3b795e7953d02d75a1
https://doi.org/10.1158/1078-0432.22488897
https://doi.org/10.1158/1078-0432.22488897
Autor:
Michael D. Farwell, Osigbemhe Iyalomhe
Publikováno v:
Radiol Clin North Am
FDG PET/CT is sensitive to the metabolic, immune-related, and structural changes that can occur in tumors in the setting of cancer immunotherapy. However, unique mechanisms of immune checkpoint inhibitors (ICIs) can occasionally make response evaluat
Autor:
Elise A. Chong, Marco Ruella, Sunita D. Nasta, Jakub Svoboda, Mitchell E. Hughes, Michael D. Farwell, Austin R. Pantel, Mark A. Sellmyer, Adam Bagg, Hatcher J. Ballard, Esin C. Namoglu, Andrew Ruff
Publikováno v:
Mol Imaging Biol
PURPOSE: (18) F-Fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) is a well-established imaging modality to assess responses in patients with B-cell neoplasms. However, there is limited information about the utility of